`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`NEPTUNE GENERICS, LLC
`Petitioner,
`
`v.
`
`CORCEPT THERAPEUTICS, INC.
`Patent Owner.
`
`____________________
`
`Case IPR2018-01494
`Patent No. 8,921,348 B2
`__________________
`
`
`NEPTUNE GENERICS, LLC’S UPDATED MANDATORY
`NOTICES PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`
`
`Mail Stop: PATENT BOARD
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`
`IPR2018-01494
`U.S. Patent No. 8,921,348
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8, Petitioner Neptune Generics, LLC, hereby
`
`submits the following updated information.
`
`I.
`
`
`
`REAL PARTY-IN-INTEREST
`
`Pursuant to 37 C.F.R. § 42.8(b)(1), Petitioner certifies the following
`
`information: Neptune Generics, LLC; Niagara FundingCo, LLC; GKC
`
`Partners II, LP; GKC General Partner II, LP; Burford Capital Ireland DAC;
`
`GKC PII Holdings, LLC; Burford Capital Investment Management LLC;
`
`Burford Capital Holdings (UK) Limited; and Burford Capital Limited are the
`
`real parties in interest (collectively, “RPI”). Neptune Generics, LLC, a New
`
`York limited liability company, is 100% owned by Niagara FundingCo, LLC,
`
`a New York limited liability company, which itself is 100% owned by GKC
`
`Partners II, LP, a Delaware limited partnership. No other person (including
`
`any investor, limited partner, or member or any other person in any of Neptune
`
`Generics, LLC, Niagara FundingCo, LLC, GKC Partners II, LP, GKC
`
`General Partner II, LP, Burford Capital Ireland DAC, GKC PII Holdings,
`
`LLC, Burford Capital Investment Management LLC, Burford Capital
`
`Holdings (UK) Limited, or Burford Capital Limited) has authority to direct or
`
`control (i) the timing of, filing of, content of, or any decisions or other
`
`activities relating to this Petition or (ii) any timing, future filings, content of,
`
`2
`
`
`
`IPR2018-01494
`U.S. Patent No. 8,921,348
`or any decisions or other activities relating to the future proceedings related
`
`to this Petition. All of the costs associated with this Petition are expected to
`
`be borne by Neptune Generics, LLC, Niagara FundingCo, LLC, GKC
`
`Partners II, LP, GKC General Partner II, LP, Burford Capital Ireland DAC,
`
`GKC PII Holdings, LLC, Burford Capital Investment Management LLC,
`
`Burford Capital Holdings (UK) Limited, and Burford Capital Limited.
`
`
`
`Date: August 28, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`
`By: /Kenneth M. Goldman/
`
`Kenneth M. Goldman
`
`Kenneth M. Goldman (Reg. No. 34,174)
`MASSEY & GAIL LLP
`50 E. Washington Street, Suite 400
`Chicago, Illinois 60602
`Telephone: (312) 283-1590
`Fax: (312) 379-0467
`Email: kgoldman@masseygail.com
`Attorneys for Petitioner
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`IPR2018-01494
`U.S. Patent No. 8,921,348
`
`
`
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned hereby certifies that a true and correct copy of the
`
`above-captioned “Neptune Generics, LLC’S Updated Mandatory Notices
`
`Pursuant to 37 C.F.R. § 42.8” was served by electronic mail on August 28,
`
`2018 upon Patent Owner’s lead and backup counsel at the following email
`
`addresses:
`
`
`
`
`
`
`
`
`
`
`
`
`
`Robert Steinberg (Reg. No. 33,144)
`Latham & Watkins LLP
`555 Eleventh Street, NW, Ste. 1000
`Washington, DC 20004-1304
`bob.steinberg@lw.com
`
`David P. Frazier (Reg. No. 47,576)
`Latham & Watkins LLP
`555 Eleventh Street, NW, Ste. 1000
`Washington, DC 20004-1304
`david.frazier@lw.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date: August 28, 2018
`
`50 E. Washington Street
`Suite 400
`
`
`
`Chicago, Illinois 60602
`
`
`
`
`
`
`
`
`
`
`
`
`/Kenneth M. Goldman/
`Kenneth M. Goldman
`Reg. No. 34,174
`Attorney for Petitioner
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`
`
`
`
`
`
`
`